You are here

Chronically Acting CFTR Inhibitor Discovery for Secretory Diarrhea and ADPKD

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK101209-01
Agency Tracking Number: R43DK101209
Amount: $224,700.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA13-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
400 Riverhills Business Park
BIRMINGHAM, AL 35242-5038
United States
DUNS: 807018333
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (205) 918-8138
Business Contact
Phone: (205) 918-8138
Research Institution

Project Summary Abstract DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen a collection of small molecular compounds on a human epithelial cell platform expressing physiologically relevant levels of the wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to discover a new class of therapeutic drugs for secretory diseases. CFTR plays a critical role in the regulation of Cl- transport and fluid secretion such that hyperactivity ofthe CFTR Cl- channel results in uncontrolled fluid secretion. Two CFTR-mediated diseases, secretory diarrhea and Autosomal Dominant Polycystic Kidney Disease (ADPKD), are driven in part by chronically active CFTR. These diseases demand treatment options that are effective and readily available due to their widespread impact on public health. Diarrheal illnesses are a leading cause of death worldwide. Despite the accepted practice of oral rehydration therapy, the incidence of secretory infection remains ala

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government